Diversity of TCR repertoire predicts recurrence after CRT followed by durvalumab in patients with NSCLC

Diversity of TCR repertoire predicts recurrence after CRT followed by durvalumab in patients with NSCLC

Abstract Chemoradiotherapy (CRT) followed by durvalumab is standard for unresectable locally advanced non-small-cell lung cancer (LA-NSCLC). This study assesses how CRT alters the T-cell receptor (TCR) repertoire in CD8 + PD-1 + T-cells and its impact on clinical outcomes. This prospective study, co...

Full description

Saved in:
Bibliographic Details
Main Authors: Masayuki Shirasawa, Tatsuya Yoshida, Takaji Matsutani, Yuki Takeyasu, Naoko Goto, Shigehiro Yagishita, Shigehisa Kitano, Hiroaki Kuroda, Toyoaki Hida, Takayasu Kurata, Yuichiro Ohe
Format: Article
Language:English
Published: Nature Portfolio 2025-01-01
Series:npj Precision Oncology
Online Access:https://doi.org/10.1038/s41698-024-00781-w
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41698-024-00781-w

Similar Items